Get the Stockscreener App
0.3585
8.94%
-0.0352
Cel-Sci Corp. stock is traded at $0.3585, with a volume of 1.09M.
It is down -8.94% in the last 24 hours and down -13.64% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$0.3937
Open:
$0.3999
24h Volume:
1.09M
Relative Volume:
0.95
Market Cap:
$27.68M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-0.7029
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
-19.58%
1M Performance:
-13.64%
6M Performance:
-67.99%
1Y Performance:
-83.17%
1-Day Range:
$0.3499
$0.3999
1-Week Range:
$0.3499
$0.6803
52-Week Range:
$0.3331
$2.4978
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
0.3585 | 27.68M | 0 | -26.92M | -18.92M | -0.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CEL-SCI advances Multikine study for head and neck cancer - Investing.com
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com
Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - StockTitan
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace
StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter
Breakthrough Cancer Treatment Shows 73% Survival Rate: CEL-SCI's Latest Clinical Milestone - StockTitan
CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World
Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA
Cel-Sci: Fiscal Q1 Earnings Snapshot -February 14, 2025 at 04:25 pm EST - Marketscreener.com
CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World
CVM: Fiscal Year 2024 Results - Research Tree
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World
Personal Finance - Business Wire
Short Interest in DoubleLine Income Solutions Fund (NYSE:DSL) Increases By 8.7% - Defense World
Have A Relaxing Holiday Season - MENAFN.COM
Cantex Mine Development (CVE:CD) Stock Price Up 9.5% – Should You Buy? - Defense World
CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Yahoo Finance
CEL-SCI's Multikine Shows 73% Survival Rate in Cancer Study, FDA Approves New Trial - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
CVM stock touches 52-week low at $0.37 amid sharp annual decline - Investing.com Nigeria
Ithaka Group LLC Sells 913 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Hanlon Investment Management Inc. Purchases 405 Shares of Microsoft Co. (NASDAQ:MSFT) - Defense World
CEL-SCI Corporation (NYSE:CVM) Announces Completion of $5 Million OfferingOn December 31, 2024, CEL-SCI Corporation, a Colorado corporation, disclosed the successful closure of an offering valued at approximately $5,000,000. The offering involved t - Defense World
Cel-Sci Stock Slips After Public Offering: Retail's Neutral - MSN
CEL-SCI completes $5 million stock offering - Investing.com
CEL-SCI Announces Closing of $5 Million Offering - Yahoo Finance
8 things to know: Big Lots strikes deal to save hundreds of stores - The Business Journals
CEL-SCI Raises $5M to Advance Multikine Cancer Therapy Development Through Strategic Stock Offering - StockTitan
CVM Stock Hits 52-Week Low at $0.42 Amid Market Challenges - Investing.com Nigeria
SEC Form 424B5 filed by Cel-Sci Corporation - Quantisnow
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket - Benzinga
5 Stocks To Watch Heading Into Monday - MSN
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
CEL-SCI Announces Pricing of $5 Million Public Offering - Yahoo Finance
CEL-SCI Announces $5M Public Offering to Advance FDA-Designated Orphan Drug Multikine Cancer Therapy - StockTitan
CEL-SCI announces proposed public offering of common stock - MSN
CEL-SCI announces common stock offering, no amount given - MSN
CVMCel-Sci Corporation Latest Stock News & Market Updates - StockTitan
CEL-SCI Announces Proposed Public Offering of Common Stock - Yahoo Finance
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
CEL-SCI (CVM) Announces Public Offering to Advance Multikine Cancer Immunotherapy Development - StockTitan
Cancer Stocks in the Spotlight: The Immunotherapy Revolution - Baystreet.ca
CEL-SCI (NYSE:CVM) Trading Down 4.4% – Should You Sell? - Defense World
Have a Relaxing Holiday Season - Baystreet.ca
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):